ARTBIO
Nick Pullen is the Chief Scientific Officer at ARTBIO. Prior to that, he held positions at Jnana Therapeutics, Bristol Myers Squibb, Celgene, Roche, and Pfizer, where he held various high-level roles in research and development. Nick's background includes a PhD in Biochemistry from the University of Southampton and extensive experience in the field of pharmaceuticals and biotechnology.
ARTBIO
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.